person · Reporting owner

TETRAULT LYNN A.

Disclosed activity across 4 companies

Tapewire entity: 32936
SEC CIK: 0001645512

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALUMIS INC.ALMS · Entity 4816	Director	June 30, 2026	July 02, 2026
NEOGENOMICS INCNEO · Entity 2096	Director	June 15, 2026	June 17, 2026
RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693	Director	June 23, 2026	June 25, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALUMIS INC.

Report date June 30, 2026 · Filed July 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,553	Reported balance After 2026-06-30 transaction · row 1 1 source row Row 1 · 2026-06-30 · Grant · Acquired 3,553 · Balance 3,553 F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant. The shares underlying this RSU vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.14 · Expires 2036-06-29	Direct	15,528	Reported balance After 2026-06-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-30 · Grant · Acquired 15,528 · Balance 15,528 F2: The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant. The shares underlying this RSU vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.

F2: The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.

NEOGENOMICS INC

Report date June 15, 2026 · Filed June 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	86,115	Reported balance After 2026-06-15 transaction · row 1 1 source row Row 1 · 2026-06-15 · Sale · Disposed 5,307 · Balance 86,115
Common StockSEC Table I · non-derivative	IndirectLynn Tetrault Rollover IRA	7,000	Reported balance Holding disclosure · report date 2026-06-15 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 7,000
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.52 · Expires 2026-06-06	Direct	2,136	Reported balance Holding disclosure · report date 2026-06-15 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance 2,136
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.54 · Expires 2027-05-28	Direct	3,448	Reported balance Holding disclosure · report date 2026-06-15 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance 3,448
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.90 · Expires 2028-06-02	Direct	3,714	Reported balance Holding disclosure · report date 2026-06-15 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance 3,714
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.76 · Expires 2028-10-11	Direct	972	Reported balance Holding disclosure · report date 2026-06-15 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance 972
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.10 · Expires 2029-06-10	Direct	13,882	Reported balance Holding disclosure · report date 2026-06-15 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance 13,882
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.82 · Expires 2033-08-10	Direct	8,353	Reported balance Holding disclosure · report date 2026-06-15 · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · Balance 8,353
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.71 · Expires 2034-06-01	Direct	8,672	Reported balance Holding disclosure · report date 2026-06-15 · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · Balance 8,672
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.28 · Expires 2035-06-01	Direct	16,107	Reported balance Holding disclosure · report date 2026-06-15 · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · Balance 16,107
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.52 · Expires 2036-06-01	Direct	11,069	Reported balance Holding disclosure · report date 2026-06-15 · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · Balance 11,069
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	15,970	Reported balance Holding disclosure · report date 2026-06-15 · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · Balance 15,970 F1: Once vested, the shares of common stock are not subject to expiration.

Filing footnotes · ownership attribution and instrument terms

F1: Once vested, the shares of common stock are not subject to expiration.

RHYTHM PHARMACEUTICALS, INC.

Report date June 23, 2026 · Filed June 25, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	11,712	Reported balance After 2026-06-23 transaction · row 1 1 source row Row 1 · 2026-06-23 · Exercise / conversion · Acquired 4,712 · Balance 11,712 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-23 · Exercise / conversion · Disposed 4,712 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: The restricted stock units are fully vested. The restricted stock units have no expiration date.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	2,324	Reported balance After 2026-06-24 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-24 · Grant · Acquired 2,324 · Balance 2,324 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $107.55 · Expires 2036-06-23	Direct	3,691	Reported balance After 2026-06-24 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-24 · Grant · Acquired 3,691 · Balance 3,691 F3: The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2: The restricted stock units are fully vested. The restricted stock units have no expiration date.

F3: The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date.

F4: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ACELYRIN, Inc.

Report date May 21, 2025 · Filed May 23, 2025

Section 16 reporting ended · disclosed 2025-05-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2034-06-06	Direct	0	Reported balance After 2025-05-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-05-21 · Disposition to issuer · Disposed 43,680 · Balance 0 F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F1: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.29 · Expires 2033-12-17	Direct	0	Reported balance After 2025-05-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-05-21 · Disposition to issuer · Disposed 89,955 · Balance 0 F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F4: 1/36 of the shares subject to the option vested on January 18, 2024, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

Filing footnotes · ownership attribution and instrument terms

F1: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.

F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares.

F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.

F4: 1/36 of the shares subject to the option vested on January 18, 2024, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 30, 2026 Filed Jul 2, 2026 22:30 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	15,528	$0.00 Strike: $28.14	$0.00	Disclosure SEC source: 0001645512-26-000003 · form4-07022026_100712.xml · derivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,528 Underlying: Common Stock · 15,528 shares Expires 2036-06-29 F2 · derivative.exercise_date: The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date. Read SEC document
June 30, 2026 Filed Jul 2, 2026 22:30 UTC	ALUMIS INC. ALMS · Entity 4816	GrantCommon Stock	3,553	$0.00	$0.00	Disclosure SEC source: 0001645512-26-000003 · form4-07022026_100712.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,553 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant. The shares underlying this RSU vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date. Read SEC document
June 24, 2026 Filed Jun 25, 2026 22:06 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	GrantRestricted Stock Units · Derivative	2,324	$0.00	$0.00	Disclosure SEC source: 0001104659-26-077864 · tm2619022-3_4seq1.xml · derivative · entry 4 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,324 Underlying: Common Stock · 2,324 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. Read SEC document
June 24, 2026 Filed Jun 25, 2026 22:06 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	GrantStock Option (right to buy) · Derivative	3,691	$0.00 Strike: $107.55	$0.00	Disclosure SEC source: 0001104659-26-077864 · tm2619022-3_4seq1.xml · derivative · entry 3 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,691 Underlying: Common Stock · 3,691 shares Expires 2036-06-23 F3 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document
June 23, 2026 Filed Jun 25, 2026 22:06 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionRestricted Stock Units · Derivative	4,712	$0.00	$0.00	Disclosure SEC source: 0001104659-26-077864 · tm2619022-3_4seq1.xml · derivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,712 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units are fully vested. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units are fully vested. The restricted stock units have no expiration date. Read SEC document
June 23, 2026 Filed Jun 25, 2026 22:06 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionCommon Stock	4,712	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-26-077864 · tm2619022-3_4seq1.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document
June 22, 2026 Filed Jun 24, 2026 20:15 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionStock Option (right to buy) · Derivative	37,000	$0.00 Strike: $28.27	$0.00	Disclosure SEC source: 0001104659-26-077305 · tm2618690-1_4seq1.xml · derivative · entry 3 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,000 shares Expires 2030-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document
June 22, 2026 Filed Jun 24, 2026 20:15 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	SaleCommon Stock	37,000	$100.32	$3,711,895.50	Disclosure SEC source: 0001104659-26-077305 · tm2618690-1_4seq1.xml · nonDerivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,000 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on December 15, 2025. F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $100.00 to $100.91. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document
June 22, 2026 Filed Jun 24, 2026 20:15 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionCommon Stock	37,000	$28.27	$1,045,990.00	Disclosure SEC source: 0001104659-26-077305 · tm2618690-1_4seq1.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 15, 2026 Filed Jun 17, 2026 20:07 UTC	NEOGENOMICS INC NEO · Entity 2096	SaleCommon Stock	5,307	$11.10	$58,907.70	Disclosure SEC source: 0001628280-26-043875 · wk-form4_1781726876.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,115 Read SEC document
June 09, 2026 Filed Jun 11, 2026 20:10 UTC	NEOGENOMICS INC NEO · Entity 2096	SaleCommon Stock	5,307	$11.29	$59,916.03	Disclosure SEC source: 0001628280-26-042506 · wk-form4_1781208627.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,422 Read SEC document
June 01, 2026 Filed Jun 3, 2026 23:47 UTC	NEOGENOMICS INC NEO · Entity 2096	GrantRestricted Stock Unit · Derivative	15,970	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001628280-26-040578 · wk-form4_1780530436.xml · derivative · entry 5 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,970 Underlying: Common Stock · 15,970 shares Expires not disclosed F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document
June 01, 2026 Filed Jun 3, 2026 23:47 UTC	NEOGENOMICS INC NEO · Entity 2096	GrantStock Option (Right to Buy) · Derivative	11,069	$0.00 Strike: $10.52	$0.00	Disclosure SEC source: 0001628280-26-040578 · wk-form4_1780530436.xml · derivative · entry 4 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,069 Underlying: Common Stock · 11,069 shares Expires 2036-06-01 Read SEC document
June 01, 2026 Filed Jun 3, 2026 23:47 UTC	NEOGENOMICS INC NEO · Entity 2096	Exercise / conversionRestricted Stock Unit · Derivative	23,077	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001628280-26-040578 · wk-form4_1780530436.xml · derivative · entry 3 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,077 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document
June 01, 2026 Filed Jun 3, 2026 23:47 UTC	NEOGENOMICS INC NEO · Entity 2096	Exercise / conversionCommon Stock	23,077	$0.00	$0.00	Disclosure SEC source: 0001628280-26-040578 · wk-form4_1780530436.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
July 30, 2025 Filed Aug 1, 2025 20:05 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	49,800	$0.00 Strike: $4.10	$0.00	Disclosure SEC source: 0001415889-25-020837 · form4-08012025_040809.xml · derivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,800 Underlying: Common Stock · 49,800 shares Expires 2035-07-29 F1 · derivative.exercise_date: The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date. Read SEC document
June 24, 2025 Filed Jun 26, 2025 20:33 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	GrantRestricted Stock Units · Derivative	4,712	$0.00	$0.00	Disclosure SEC source: 0001104659-25-063068 · tm2519230-2_4seq1.xml · derivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,712 Underlying: Common Stock · 4,712 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. Read SEC document
June 24, 2025 Filed Jun 26, 2025 20:33 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	GrantStock Option (right to buy) · Derivative	7,037	$0.00 Strike: $63.66	$0.00	Disclosure SEC source: 0001104659-25-063068 · tm2519230-2_4seq1.xml · derivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,037 Underlying: Common Stock · 7,037 shares Expires 2035-06-23 F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. Read SEC document
June 18, 2025 Filed Jun 23, 2025 20:48 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionRestricted Stock Units · Derivative	4,000	$0.00	$0.00	Disclosure SEC source: 0001104659-25-061704 · tm2518591-1_4seq1.xml · derivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units fully vested on June 18, 2025. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units fully vested on June 18, 2025. The restricted stock units have no expiration date. Read SEC document
June 18, 2025 Filed Jun 23, 2025 20:48 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionCommon Stock	4,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-25-061704 · tm2518591-1_4seq1.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document
June 01, 2025 Filed Jun 3, 2025 20:07 UTC	NEOGENOMICS INC NEO · Entity 2096	GrantRestricted Stock Unit · Derivative	23,077	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001077183-25-000127 · wk-form4_1748981256.xml · derivative · entry 5 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,077 Underlying: Common Stock · 23,077 shares Expires not disclosed F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document
June 01, 2025 Filed Jun 3, 2025 20:07 UTC	NEOGENOMICS INC NEO · Entity 2096	GrantStock Option (Right to Buy) · Derivative	16,107	$0.00 Strike: $7.28	$0.00	Disclosure SEC source: 0001077183-25-000127 · wk-form4_1748981256.xml · derivative · entry 4 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,107 Underlying: Common Stock · 16,107 shares Expires 2035-06-01 Read SEC document
June 01, 2025 Filed Jun 3, 2025 20:07 UTC	NEOGENOMICS INC NEO · Entity 2096	Exercise / conversionRestricted Stock Unit · Derivative	12,254	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001077183-25-000127 · wk-form4_1748981256.xml · derivative · entry 3 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,254 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document
June 01, 2025 Filed Jun 3, 2025 20:07 UTC	NEOGENOMICS INC NEO · Entity 2096	Exercise / conversionCommon Stock	12,254	$0.00	$0.00	Disclosure SEC source: 0001077183-25-000127 · wk-form4_1748981256.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
May 21, 2025 Filed May 23, 2025 20:04 UTC	ACELYRIN, Inc. SLRN · Entity 79310	Disposition to issuerDirector Stock Option (right to buy) · Derivative	89,955	Not disclosed Strike: $7.29	Not disclosed	Disclosure SEC source: 0001962918-25-000050 · wk-form4_1748030649.xml · derivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 89,955 shares Expires 2033-12-17 F2 · price: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3 · price: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F4 · derivative.exercise_date: 1/36 of the shares subject to the option vested on January 18, 2024, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document
May 21, 2025 Filed May 23, 2025 20:04 UTC	ACELYRIN, Inc. SLRN · Entity 79310	Disposition to issuerDirector Stock Option (right to buy) · Derivative	43,680	Not disclosed Strike: $4.46	Not disclosed	Disclosure SEC source: 0001962918-25-000050 · wk-form4_1748030649.xml · derivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,680 shares Expires 2034-06-06 F2 · price: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3 · price: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F1 · derivative.exercise_date: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document
May 09, 2025 Filed May 9, 2025 21:26 UTC	NEOGENOMICS INC NEO · Entity 2096	PurchaseCommon Stock	7,000	$8.14	$56,974.40	Disclosure SEC source: 0001077183-25-000100 · wk-form4_1746826010.xml · nonDerivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Lynn Tetrault Rollover IRA Disclosed balance after: 7,000 Read SEC document
September 10, 2024 Filed Sep 11, 2024 20:31 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionStock Option (right to buy) · Derivative	7,501	$0.00 Strike: $18.99	$0.00	Disclosure SEC source: 0001104659-24-098944 · tm2423816-2_4seq1.xml · derivative · entry 10 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,501 shares Expires 2031-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document
September 10, 2024 Filed Sep 11, 2024 20:31 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $4.15	$0.00	Disclosure SEC source: 0001104659-24-098944 · tm2423816-2_4seq1.xml · derivative · entry 9 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2032-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document
September 10, 2024 Filed Sep 11, 2024 20:31 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	SaleCommon Stock	350	$50.60	$17,709.51	Disclosure SEC source: 0001104659-24-098944 · tm2423816-2_4seq1.xml · nonDerivative · entry 7 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,000 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 13, 2024. F5 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $50.55 to $50.71. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document
September 10, 2024 Filed Sep 11, 2024 20:31 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	SaleCommon Stock	8,661	$50.20	$434,796.06	Disclosure SEC source: 0001104659-24-098944 · tm2423816-2_4seq1.xml · nonDerivative · entry 6 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,350 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 13, 2024. F4 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $49.54 to $50.50. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document
September 10, 2024 Filed Sep 11, 2024 20:31 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	SaleCommon Stock	8,490	$49.05	$416,417.52	Disclosure SEC source: 0001104659-24-098944 · tm2423816-2_4seq1.xml · nonDerivative · entry 5 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,011 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 13, 2024. F3 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $48.53 to $49.52. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document
September 10, 2024 Filed Sep 11, 2024 20:31 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionCommon Stock	7,501	$18.99	$142,443.99	Disclosure SEC source: 0001104659-24-098944 · tm2423816-2_4seq1.xml · nonDerivative · entry 4 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 10, 2024 Filed Sep 11, 2024 20:31 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionCommon Stock	10,000	$4.15	$41,500.00	Disclosure SEC source: 0001104659-24-098944 · tm2423816-2_4seq1.xml · nonDerivative · entry 3 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 09, 2024 Filed Sep 11, 2024 20:31 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionStock Option (right to buy) · Derivative	3,199	$0.00 Strike: $18.99	$0.00	Disclosure SEC source: 0001104659-24-098944 · tm2423816-2_4seq1.xml · derivative · entry 8 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,501 Underlying: Common Stock · 3,199 shares Expires 2031-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document
September 09, 2024 Filed Sep 11, 2024 20:31 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	SaleCommon Stock	3,199	$50.04	$160,068.04	Disclosure SEC source: 0001104659-24-098944 · tm2423816-2_4seq1.xml · nonDerivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,000 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 13, 2024. F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $50.00 to $50.25. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document
September 09, 2024 Filed Sep 11, 2024 20:31 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionCommon Stock	3,199	$18.99	$60,749.01	Disclosure SEC source: 0001104659-24-098944 · tm2423816-2_4seq1.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 26, 2024 Filed Aug 28, 2024 20:31 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionStock Option (right to buy) · Derivative	4,300	$0.00 Strike: $18.99	$0.00	Disclosure SEC source: 0001104659-24-094012 · tm2422915-2_4seq1.xml · derivative · entry 3 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,700 Underlying: Common Stock · 4,300 shares Expires 2031-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document
August 26, 2024 Filed Aug 28, 2024 20:31 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	SaleCommon Stock	4,300	$50.01	$215,028.81	Disclosure SEC source: 0001104659-24-094012 · tm2422915-2_4seq1.xml · nonDerivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,000 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 13, 2024. F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $50.00 to $50.03. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document
August 26, 2024 Filed Aug 28, 2024 20:31 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionCommon Stock	4,300	$18.99	$81,657.00	Disclosure SEC source: 0001104659-24-094012 · tm2422915-2_4seq1.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 12, 2024 Filed Aug 14, 2024 20:15 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $4.15	$0.00	Disclosure SEC source: 0001104659-24-089634 · tm2421587-2_4seq1.xml · derivative · entry 4 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document
August 12, 2024 Filed Aug 14, 2024 20:15 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	SaleCommon Stock	407	$45.37	$18,466.28	Disclosure SEC source: 0001104659-24-089634 · tm2421587-2_4seq1.xml · nonDerivative · entry 3 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,000 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 13, 2024. F3 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $45.35 to $45.61. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document
August 12, 2024 Filed Aug 14, 2024 20:15 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	SaleCommon Stock	9,593	$44.62	$427,995.53	Disclosure SEC source: 0001104659-24-089634 · tm2421587-2_4seq1.xml · nonDerivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,407 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 13, 2024. F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $44.32 to $45.19. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document
August 12, 2024 Filed Aug 14, 2024 20:15 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionCommon Stock	10,000	$4.15	$41,500.00	Disclosure SEC source: 0001104659-24-089634 · tm2421587-2_4seq1.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 10, 2024 Filed Aug 13, 2024 20:37 UTC	NEOGENOMICS INC NEO · Entity 2096	Exercise / conversionRestricted Stock Unit · Derivative	11,336	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001077183-24-000135 · wk-form4_1723581438.xml · derivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,336 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document
August 10, 2024 Filed Aug 13, 2024 20:37 UTC	NEOGENOMICS INC NEO · Entity 2096	Exercise / conversionCommon Stock	11,336	$0.00	$0.00	Disclosure SEC source: 0001077183-24-000135 · wk-form4_1723581438.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
June 21, 2024 Filed Jun 25, 2024 20:38 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionRestricted Stock Units · Derivative	3,000	$0.00	$0.00	Disclosure SEC source: 0001104659-24-074768 · tm2418139-4_4seq1.xml · derivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units fully vested on June 21, 2024. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units fully vested on June 21, 2024. The restricted stock units have no expiration date. Read SEC document
June 21, 2024 Filed Jun 25, 2024 20:38 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionCommon Stock	3,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-074768 · tm2418139-4_4seq1.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document
June 18, 2024 Filed Jun 21, 2024 01:47 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	GrantRestricted Stock Units · Derivative	4,000	$0.00	$0.00	Disclosure SEC source: 0001104659-24-073638 · tm2417588-7_4seq1.xml · derivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. Read SEC document
June 18, 2024 Filed Jun 21, 2024 01:47 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	GrantStock Option (right to buy) · Derivative	14,000	$0.00 Strike: $41.39	$0.00	Disclosure SEC source: 0001104659-24-073638 · tm2417588-7_4seq1.xml · derivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2034-06-17 F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.